The use of lenvatinib and pembrolizumab after platinumbased chemotherapy in advanced endometrial cancer

Abstract

Endometrial cancer is a common cancer in women. While there are several treatment options, there is a need for newer, more effective therapies. One such option is combining lenvatinib, a targeted therapy, with pembrolizumab, an immunotherapy. This combination has shown promising results in treating advanced endometrial cancer, especially after patients have undergone chemotherapy with platinum-based drugs. However, more research is needed to fully understand its benefits and risks. This case report presents a patient with recurrent disease treated with lenvatinib and pembrolizumab, highlighting its potential efficacy.